Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 2/20 | 0.67 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.67 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.44 |
| ▸ | VEGFA | P15692 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25934714 | 0.82 | FTO (0.74) | FTOEGLN2TLR7L3MBTL1EGLN1 | |
| SCHEMBL704958 | 0.80 | FTO (1.00) | FTOEGLN2TLR7EGLN1VEGFA | |
| SCHEMBL8779266 | 0.79 | EGLN2 (0.70) | FTOEGLN2TLR7EGLN1VEGFA | |
| SCHEMBL14122981 | 0.79 | FTO (0.74) | FTOEGLN2TLR7L3MBTL1EGLN1 | |
| SCHEMBL25934858 | 0.79 | FTO (0.65) | FTOEGLN2TLR7EGLN1VEGFA | |
| SCHEMBL23514351 | 0.79 | FTO (0.69) | FTOEGLN2TLR7L3MBTL1PIM1 | |
| SCHEMBL3724024 | 0.76 | EGLN2 (0.60) | FTOEGLN2TLR7L3MBTL1RAB9A | |
| SCHEMBL1921385 | 0.76 | EGLN2 (0.65) | FTOEGLN2TLR7L3MBTL1EGLN1 | |
| SCHEMBL24405060 | 0.76 | FTO (0.69) | FTOEGLN2TLR7L3MBTL1EGLN1 | |
| SCHEMBL25934739 | 0.76 | EGLN2 (0.65) | FTOEGLN2TLR7EGLN1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248717-A1 | N-(3-HYDROXYPYRIDINE-2-CARBONYL)GLYCINE-BASED ANTITUMOR DRUG SENSITIZER AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY (CN) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248717-A1 | N-(3-HYDROXYPYRIDINE-2-CARBONYL)GLYCINE-BASED ANTITUMOR DRUG SENSITIZER AND APPLICATION THEREOF | IDO1, PDCD1, IDO2 | FTO 1432/4885EGLN2 21/4885TLR7 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.